Sirolimus

Overview

Sirolimus, also known as rapamycin, is an immunosuppressive drug commonly used to prevent organ transplant rejection. It works by inhibiting the mammalian target of rapamycin (mTOR), which plays a crucial role in cell growth and proliferation.

API suppliers (12)

Suppliers of Sirolimus backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• FUJIAN KERUI PHARMACEUTICAL CO LTDChina1 active DMF
• FUJIAN KERUI PHARMACEUTICAL CO LTDChina1 active DMF
• CURIA ITALY SRL1 active DMF
• FUJIAN KERUI PHARMACEUTICAL CO LTDChina1 active DMF
• Lonza Group AGSwitzerland1 active DMF
• CURIA ITALY SRL1 active DMF
• FUJIAN KERUI PHARMACEUTICAL CO LTDChina1 active DMF
• Lonza Group AGSwitzerland1 active DMF
• CURIA ITALY SRL1 active DMF
• CONCORD BIOTECH LTD1 active DMF
• Zhejiang Hisun Pharmaceutical Co., Ltd.China1 active DMF
• HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTDChina

Patent & exclusivity (US)

Per the FDA Orange Book (23 approved US products), the latest listed US patent on Sirolimus expires 27 Oct 2040 and exclusivity 22 Mar 2029. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

1,18-dihydroxy-12-[1-(4-hydroxy-3-methoxycyclohexyl)propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

Canonical SMILES

CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC

InChIKey

QFJCIRLUMZQUOT-UHFFFAOYSA-N

Therapeutic areas